Geographical distribution of HIV‐1 group O viruses in Africa

  title={Geographical distribution of HIV‐1 group O viruses in Africa},
  author={Martine Peeters and A{\"i}ssatou Gueye and Souleymane Mboup and Frédéric Bibollet-Ruche and Euloge Ekaza and Claire Mulanga and Rasmata Ouedrago and Regine Gandji and P Mpele and G Dibanga and B Koumare and Mamadou Saidou and Eka Esu-Williams and Jean Pierre Lombart and Wanta Badombena and Nkandu Luo and Marleen Vanden Haesevelde and Eric Delaporte},
Objective:To determine to what extent HIV-1 group O strains are present in different African countries. Materials and methods:A total of 14 682 samples of sera from a range of patients from 12 different African countries were tested. All the sera were tested with an enzyme-linked immunosorbent assay (ELISA) using a combination of V3 peptides from ANT-70 and MVP-5180. Samples reactive in ELISA were retested in a line immunoassay (LIA-O). Samples reactive in ELISA were also retested with an in… 
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detection.
The results show that optimal specificity rather than optimal sensitivity makes the V3 PEIA a sufficiently accurate epidemiological tool to be useful in estimating specifically group O infection among HIV-1-infected patients.
HIV type-1 group O infection in Gabon: low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains.
Even if HIV-1/O infection is low in Gabon, an accurate diagnosis and a reliable virological follow-up are required in Central Africa to optimize ARV treatments of HIV- 1/O-infected patients.
Role of Human Immunodeficiency Virus Type 1 Group O in the AIDS Pandemic
Differences in biological characteristics between groups M and O could explain for reduced spread of HIV-1 group O and ultimately shed light on the factors contributing to the HIV- 1 group M epidemic.
Severe underquantification of HIV-1 group O isolates by major commercial PCR-based assays.
  • A. Berger, M. Muenchhoff, O. Keppler
  • Biology, Medicine
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2020
HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections.
The results show that the HIV epidemic in northwest Cameroon is dominated by HIV-1 group M CRF02_AG infections (57%) and additional group M subtypes present include A, D, F2, G, and CRF01_AE, while group O prevalence is low and group O strain diversity is high.
HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.
Molecular genotyping of HIV‐1 in 61 patients with AIDS from Lomé, Togo
To study the distribution of HIV types and genotypes, in Lomé, Togo, a random population of patients who met the clinical criteria of the Bangui definition of AIDS and were positive with two


Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France
The level of diversity among group O sequences suggests that they may have a comparable (or greater) age than the M group sequences, although for unknown reasons, the latter group dispersed first and is the dominant lineage in the pandemic.
Antigenic evidence of the presence of the aberrant HIV‐1ANT70 virus in Cameroon and Gabon
The authors suggest that the results of a research project on the prevalence of sera collected from HIV-1 positive people in Cameroon Gabon Ivory Coast and Kenya which are reactive to a genetically divergent HIV-2 V3 peptide isolate (ANT70) and peptides obtained from 3 other HIV- 1 isolates should prompt further investigation in mapping antigenic diversity in Africa.
Prevalence of HIV-1 subtype O infection in Cameroon: preliminary results.
This study found that the prevalence of HIV-1 subtype O infection in Cameroon is 2.0% or less, which accounts for less than 10% of all HIV- 1 cases in Cameroon.
Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon.
Seroreactivity in the HIVant70 V3 loop peptide ELISA leads to the identification of viruses genetically related to HIVant69 and within this cluster HIVca9 and HIVvi686 are more closely related toAIDS than to the HIVmvp5180 isolate.
Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV‐1ANT‐70 isolate in human sera from different geographic regions
V3 peptide serology using the very specific V3 loop peptide of the HIVANT-70 is a good indicator of the very aberrant group O in a particular population.